A concise review : the synergy between artificial intelligence and biomedical nanomaterials that empowers nanomedicine
© 2021 IOP Publishing Ltd..
Nanomedicine has recently experienced unprecedented growth and development. However, the complexity of operations at the nanoscale introduces a layer of difficulty in the clinical translation of nanodrugs and biomedical nanotechnology. This problem is further exacerbated when engineering and optimizing nanomaterials for biomedical purposes. To navigate this issue, artificial intelligence (AI) algorithms have been applied for data analysis and inference, allowing for a more applicable understanding of the complex interaction amongst the abundant variables in a system involving the synthesis or use of nanomedicine. Here, we report on the current relationship and implications of nanomedicine and AI. Particularly, we explore AI as a tool for enabling nanomedicine in the context of nanodrug screening and development, brain-machine interfaces and nanotoxicology. We also report on the current state and future direction of nanomedicine and AI in cancer, diabetes, and neurological disorder therapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Biomedical materials (Bristol, England) - 16(2021), 5 vom: 05. Aug. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hayat, Hasaan [VerfasserIn] |
---|
Links: |
---|
Themen: |
Artificial intelligence |
---|
Anmerkungen: |
Date Completed 25.02.2022 Date Revised 25.02.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1088/1748-605X/ac15b2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM328262080 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM328262080 | ||
003 | DE-627 | ||
005 | 20231225202601.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1088/1748-605X/ac15b2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1094.xml |
035 | |a (DE-627)NLM328262080 | ||
035 | |a (NLM)34280907 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hayat, Hasaan |e verfasserin |4 aut | |
245 | 1 | 2 | |a A concise review |b the synergy between artificial intelligence and biomedical nanomaterials that empowers nanomedicine |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.02.2022 | ||
500 | |a Date Revised 25.02.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 IOP Publishing Ltd. | ||
520 | |a Nanomedicine has recently experienced unprecedented growth and development. However, the complexity of operations at the nanoscale introduces a layer of difficulty in the clinical translation of nanodrugs and biomedical nanotechnology. This problem is further exacerbated when engineering and optimizing nanomaterials for biomedical purposes. To navigate this issue, artificial intelligence (AI) algorithms have been applied for data analysis and inference, allowing for a more applicable understanding of the complex interaction amongst the abundant variables in a system involving the synthesis or use of nanomedicine. Here, we report on the current relationship and implications of nanomedicine and AI. Particularly, we explore AI as a tool for enabling nanomedicine in the context of nanodrug screening and development, brain-machine interfaces and nanotoxicology. We also report on the current state and future direction of nanomedicine and AI in cancer, diabetes, and neurological disorder therapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a artificial intelligence | |
650 | 4 | |a cancer | |
650 | 4 | |a deep learning | |
650 | 4 | |a machine learning | |
650 | 4 | |a nanomedicine | |
650 | 4 | |a nanotechnology | |
650 | 4 | |a type 1 diabetes | |
650 | 7 | |a Biocompatible Materials |2 NLM | |
700 | 1 | |a Nukala, Arijit |e verfasserin |4 aut | |
700 | 1 | |a Nyamira, Anthony |e verfasserin |4 aut | |
700 | 1 | |a Fan, Jinda |e verfasserin |4 aut | |
700 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biomedical materials (Bristol, England) |d 2006 |g 16(2021), 5 vom: 05. Aug. |w (DE-627)NLM179364588 |x 1748-605X |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2021 |g number:5 |g day:05 |g month:08 |
856 | 4 | 0 | |u http://dx.doi.org/10.1088/1748-605X/ac15b2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2021 |e 5 |b 05 |c 08 |